BRPI0921371A2 - Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas. - Google Patents

Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.

Info

Publication number
BRPI0921371A2
BRPI0921371A2 BRPI0921371-6A2A BRPI0921371A BRPI0921371A2 BR PI0921371 A2 BRPI0921371 A2 BR PI0921371A2 BR PI0921371 A BRPI0921371 A BR PI0921371A BR PI0921371 A2 BRPI0921371 A2 BR PI0921371A2
Authority
BR
Brazil
Prior art keywords
inducing
derived
stem cells
therapeutic use
human monocyte
Prior art date
Application number
BRPI0921371-6A2A
Other languages
English (en)
Inventor
Hisanobu Hirano
Yasushi Ohkubo
Kenjiro Sasaki
Hironobu Ishiyama
Original Assignee
Otsuka Pharmaceutica Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutica Co Ltd filed Critical Otsuka Pharmaceutica Co Ltd
Publication of BRPI0921371A2 publication Critical patent/BRPI0921371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
BRPI0921371-6A2A 2008-11-25 2009-11-19 Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas. BRPI0921371A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008299359 2008-11-25
PCT/JP2009/069648 WO2010061781A1 (ja) 2008-11-25 2009-11-19 ヒト単球由来治療用幹細胞およびその誘導方法

Publications (1)

Publication Number Publication Date
BRPI0921371A2 true BRPI0921371A2 (pt) 2014-11-18

Family

ID=42225657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921371-6A2A BRPI0921371A2 (pt) 2008-11-25 2009-11-19 Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.

Country Status (17)

Country Link
US (2) US9169463B2 (pt)
EP (1) EP2365061A4 (pt)
JP (1) JP5800505B2 (pt)
KR (1) KR101682731B1 (pt)
CN (1) CN102245757B (pt)
AR (1) AR074406A1 (pt)
AU (1) AU2009320881B2 (pt)
BR (1) BRPI0921371A2 (pt)
CA (3) CA2744289A1 (pt)
CO (1) CO6341484A2 (pt)
IL (1) IL212638A (pt)
MX (1) MX336067B (pt)
RU (1) RU2573906C2 (pt)
TW (1) TWI539000B (pt)
UA (1) UA110691C2 (pt)
WO (1) WO2010061781A1 (pt)
ZA (1) ZA201103268B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399741A (zh) * 2010-09-19 2012-04-04 林雄斌 逆向分化体细胞产生造血干细胞的培养液、方法及用途
EP3524254A4 (en) * 2016-09-14 2020-11-11 Tes Holdings Co., Ltd. LIN28A ACTIVATOR AND USE OF IT
CN107904202B (zh) * 2017-11-22 2018-11-20 北京恩诺生物科技有限公司 一种制备多能干细胞样细胞的方法、组合物和应用
JP6375076B1 (ja) * 2018-02-19 2018-08-15 株式会社 バイオミメティクスシンパシーズ 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法
JP6574292B2 (ja) * 2018-07-21 2019-09-11 株式会社 バイオミメティクスシンパシーズ 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778787A (en) * 1985-12-20 1988-10-18 Trustees Of Boston University Method for treatment of angina and myocardial infarctions with omental lipids
US5272138A (en) * 1988-02-12 1993-12-21 The Biomembrane Institute Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology
US6084060A (en) * 1996-12-09 2000-07-04 Imclone Systems Incorporated Composition and method for preserving progenitor cells
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
DE10214095C1 (de) * 2002-03-28 2003-09-25 Bernd Karl Friedrich Kremer Dedifferenzierte, programmierbare Stammzellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
WO2004087063A2 (en) 2003-03-27 2004-10-14 Janssen Pharmaceutica Nv Use of erythropoietin in stroke recovery
NZ548049A (en) * 2003-12-02 2009-01-31 Celgene Corp Methods and compositions for the treatment and management of hemoglobinopathy and anemia
WO2005085422A1 (en) * 2004-02-27 2005-09-15 Michigan State University Adult stem cells and uses thereof
WO2008083233A2 (en) 2006-12-29 2008-07-10 Dow Agrosciences Llc In vitro methods for the induction and maintenance of plant cell lines as single suspension cells with intact cell walls, and transformation thereof

Also Published As

Publication number Publication date
AU2009320881A1 (en) 2010-06-03
RU2011126165A (ru) 2013-01-10
US20110223143A1 (en) 2011-09-15
IL212638A (en) 2017-08-31
EP2365061A4 (en) 2013-03-13
TWI539000B (zh) 2016-06-21
CN102245757A (zh) 2011-11-16
KR101682731B1 (ko) 2016-12-05
JPWO2010061781A1 (ja) 2012-04-26
CO6341484A2 (es) 2011-11-21
AR074406A1 (es) 2011-01-12
ZA201103268B (en) 2012-07-25
EP2365061A1 (en) 2011-09-14
WO2010061781A1 (ja) 2010-06-03
UA110691C2 (uk) 2016-02-10
RU2573906C2 (ru) 2016-01-27
US9169463B2 (en) 2015-10-27
CN102245757B (zh) 2014-11-26
CA2977820A1 (en) 2010-06-03
AU2009320881B2 (en) 2015-01-22
IL212638A0 (en) 2011-07-31
TW201024415A (en) 2010-07-01
MX336067B (es) 2016-01-06
KR20110094084A (ko) 2011-08-19
JP5800505B2 (ja) 2015-10-28
CA2977823A1 (en) 2010-06-03
MX2011005480A (es) 2011-06-20
CA2744289A1 (en) 2010-06-03
US20160008434A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
BRPI0822756A2 (pt) sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca.
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
PL2202470T3 (pl) Sposób i system wykorzystywania energii odnawialnych
BRPI0816151A2 (pt) válvula utilizável com um poço, sistema usável com um poço, e método usável com um poço
BRPI0813757A2 (pt) Sistema de implante, e, método
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI1011886A2 (pt) solução contendo ácido hiplocloroso e métodos do uso do mesmo.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0811750A2 (pt) Método para produzir um inversor de enriquecimento-empobrecimento, e, inversor
BRPI0907054A2 (pt) sistema de aeronave, e, método para operar um sistema de aeronave
BRPI1006885A2 (pt) sistema de completação utilizável com um poço, e método utilizável com um poço
BRPI0920891A2 (pt) misturas de alfa-amilase e métodos para uso das referidas misturas
BRPI0822218A2 (pt) Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
BRPI1006996A2 (pt) composição, método e uso
BRPI0924528A2 (pt) gerador de radionuclídeo e método para esterilização.
BRPI0911252A2 (pt) método, extrato, e, composição.
DK2370206T3 (da) Katalysatorbærer, fremgangsmåde til fremstilling og anvendelse af denne
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI1014960A2 (pt) sistema para uso em uma aplicação de poço submarino, e método

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.